Anticancer drug cis-4-hydroxy-L-proline: Correlation of preclinical toxicology with clinical parameters of liver function

Molecular Medicine Reports

Volumn 1, Issue 4, 2008, Pages 459-464

  Dickens, Heather ^a   Ullrich, Anett ^b   Runge, Dieter ^b   Mueller, Berno ^c   Olszewski, Ulrike ^d   Hamilton, Gerhard ^d  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Primacyt Cell Culture Technologies   (Germany)

^c RIEMSER Arzneimittel   (Germany)

^d Ludwig Boltzmann Cluster Translational Oncology ^*  (Austria)

Author keywords

cis 4 hydroxy L proline; Hepatocyte; Liver; Preclinical testing; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HYDROXYPROLINE; LACTATE DEHYDROGENASE; UREA;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CANCER; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; MALE; NONHUMAN; PELVIS CANCER; PROSTATE CANCER; RAT; REPEATED DRUG DOSE;

ANIMALIA; CHANDIPURA VIRUS; RATTUS;

EID: 69249102606     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.1.4.459     Document Type: Article

References (23)

1. Sistare FD and De George JJ: Preclinical predictors of clinical safety: opportunities for improvement. Clin Pharmacol Ther 82: 210-214, 2007. (Pubitemid 47075341)
2. Rodriguez-Frias EA and Lee WM: Cancer chemotherapy I: hepatocellular injury. Clin Liver Dis 11: 641-662, 2007.
3. Floyd J, Mirza I, Sachs B and Perry MC: Hepatotoxicity of chemotherapy. Semin Oncol 33: 50-67, 2006.
4. Takeuchi T and Prockop DJ: Biosynthesis of abnormal collagens with amino acid analogues. I. Incorporation of L-azetidine-2-carboxylic acid and cis-4-fluoro-L-proline into protocollagen and collagen. Biochim Biophys Acta 175: 142-155, 1969.
5. Rosenboom J and Prockop DJ: Incorporation of cis-hydroxy-L-proline into protocollagen and collagen. J Biol Chem 246: 1549-1555, 1971.
6. Uitto J, Hoffmann HP and Prockop DJ: Retention of non-helical procollagen containing cis-hydroxy-L-proline in rough endoplasmic reticulum. Science 190: 1202-1204, 1975.
7. Lewko WM, Liotta LA and Wicha MS: Sensitivity of N-nitrosomethylurea- induced rat mammary tumors to cis-hydroxy-L-proline, an inhibitor of collagen production. Cancer Res 41: 2855-2862, 1981.
8. Klohs WD, Steinkampf RW, Wicha MS, Mertus AE, Tunac JB and Leopold WR: Collagen-production inhibitors evaluated as antitumor agents. J Natl Cancer Inst 75: 353-359, 1985.
9. Mueller C, Emmrich J, Jaster R, Braun D, Liebe S and Sparmann G: Cis-4-hydrox-L-proline-induced inhibition of pancreatic cancer cell growth is mediated by endoplasmic reticulum stress. World J Gastroenterol 12: 1569-1576, 2006.
10. Olszewski U, Ellinger A, Zeillinger R, Baumgartner G and Hamilton G: Involvement of 14-3-3sigma in cytotoxicity of cis-4-hydroxy-L-proline (CHP) against epithelial tumor cell lines. FEBS 2008, Proceedings, C2-152.
11. Runge D, Michalopoulos GK, Strom SC and Runge DM: Recent advances in human hepatocyte culture. Biochem Biophys Res Commun 274: 1-3, 2000. (Pubitemid 30496747)
12. Van de Bovenkamp M, Groothuis GM, Meijer DK and Olinga P: Liver fibrosis in vitro: cell culture models and precision-cut liver slices. Toxicol In Vitro 21: 545-557, 2007. (Pubitemid 46550745)
13. Battle T and Stacey G: Cell culture models for hepatotoxicology. Cell Biol Toxicol 17: 287-299, 2001.
14. Nussler AK, et al: The suitability of hepatocyte culture models to study various aspects of drug metabolism. ALTEX 18: 91-101, 2001.
15. Lee J, Morgan JR, Tompkins RG and Yarmush ML: L-proline-mediated enhancement of hepatocyte function in a collagen gel sandwich culture configuration. FASEB J 7: 586-591, 1993. (Pubitemid 23120907)
16. Moshage H and Yap SH: Primary cultures of human hepatocytes: a unique system for studies in toxicology, virology, parasitology and liver pathophysiology in man. J Hepatol 3: 404-413, 1992.
17. Li AP: Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem Biol Interact 168: 16-29, 2007.
18. Ullrich A, Berg C, Hengstler JG and Runge D: Use of a standardised and validated long-term human hepatocyte culture system for repetitive analyses of drugs: repeated administrations of acetaminophen reduces albumin and urea secretion. ALTEX 24: 35-40, 2007. (Pubitemid 46563942)
19. Strom SC, Jirtle RL, Jones RS, et al: Isolation, culture and transplantation of human hepatocytes. J Natl Cancer Inst 68: 771-778, 1982. (Pubitemid 12070932)
20. Strom SC, Monteith DL, Manoharan K and Novotny AL: Genetic toxicology studies with human hepatocytes. In: The Isolated Hepatocyte: Use in Toxicology and Xenobiotic Biotransformation. Rauckman EJ and Padilla GM (eds). Academic Press, Orlando, FL, pp265-280, 1987.
21. Nakamura T, Teramoto H, Tomita Y and Ichihara A: L-proline is an essential amino acid for hepatocyte growth in culture. Biochem Biophys Res Commun 122: 884-891, 1984. (Pubitemid 14027603)
22. Runge D, Köhler C, Kostrubsky VE, Jaeger D, Lehmann T, Runge DM, May U, Beer Stolz D, Strom SC, Fleig WE and Michalopoulos GK: Induction of cytochrome P450 CYP1A1, CYP1A2 and CYP3A4 but not of CYP2C9, CYP2C19, multi-drug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun 273: 333-341, 2000. (Pubitemid 30426907)
23. Li AP, Maurel P, Gomez-Lechon MJ, et al: Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact 107: 5-16, 1997. (Pubitemid 27508997)